Second Point- If we signed with Beckman, we would have access to a much larger parent company (Danaher). Sort of like the ebio/affy deal.
Third point- Last summer, Beckman received a warning letter from the U.S. Food and Drug Administration saying the company marketed a test for heart problems without proper clearance. The test, called AccuTnI, measures a protein called troponin that is a marker for heart problems. The FDA letter said the company had made “significant modifications” to the product without getting the required regulatory clearance.
Were the "significant modifications" mix n go? lol.
Fourth and final point- Flow Cytometry instruments, such as the Gallios Flow Cytometer, characterize cell populations of interest to researchers — and Beckman Coulter holds a number two position in this segment...
Flowcytometry.....hmmmm. sounds a little familiar to me.
Thanks twin, great find as always.
ADO Price at posting:
6.7¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)